Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Comprehensive neuropsychological assessment and FDG-PET imaging in patients with RFC1-related disorder.

Parkinsonism & related disorders·2026
Same author

Targeted neurological screening for RFC1-related disease in unexplained chronic cough.

Journal of neurology·2026
Same author

Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.

Annals of neurology·2024
Same author

RTN2 deficiency results in an autosomal recessive distal motor neuropathy with lower limb spasticity.

Brain : a journal of neurology·2024
Same author

Expanding the Clinical Spectrum of <i>DRP2</i>-Associated Charcot-Marie-Tooth Disease.

Neurology·2024
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

FTY720 (fingolimod) for relapsing multiple sclerosis.

Alejandro Horga1, Xavier Montalban

  • 1Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Barcelona, Spain. ahorga@comb.es

Expert Review of Neurotherapeutics
|May 7, 2008
PubMed
Summary
This summary is machine-generated.

FTY720 (fingolimod) shows promise for treating multiple sclerosis by modulating immune responses and potentially aiding CNS repair. Clinical trials indicate its effectiveness in reducing disease activity with a good safety profile.

Related Experiment Videos

Last Updated: Jul 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Cell Biology

Background:

  • FTY720 (fingolimod) is a sphingosine analogue targeting sphingosine-1-phosphate receptors.
  • Its immunomodulatory effects involve lymphocyte sequestration in lymphoid organs.
  • Emerging data suggest FTY720 also impacts central nervous system (CNS) glial cells, potentially aiding tissue repair.

Purpose of the Study:

  • To review the therapeutic potential of FTY720 in multiple sclerosis (MS).
  • To discuss its mechanism of action, including immunomodulation and direct CNS effects.
  • To summarize clinical trial findings and ongoing research.

Main Methods:

  • Review of preclinical data in animal models of MS.
  • Analysis of Phase II clinical trial results for relapsing MS.
  • Consideration of ongoing Phase III trials for relapsing-remitting MS.

Main Results:

  • FTY720 demonstrates therapeutic effects in MS animal models.
  • A Phase II study confirmed oral FTY720 reduces disease activity in relapsing MS.
  • The drug exhibited a favorable adverse-effect profile in Phase II trials.

Conclusions:

  • FTY720 is a promising therapeutic agent for multiple sclerosis.
  • Its efficacy is supported by preclinical and early clinical data.
  • Ongoing Phase III trials will further validate its use in relapsing-remitting MS.